NCT06388551尚未招募1 期
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, SAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral LPM526000133 Fumarate Capsules (LY03017) in Healthy Adult Subjects.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
研究概览
简要总结
This is a phase 1，randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability and pharmacokinetics of oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subject who voluntarily participate and sign the informed consent form.
- •Healthy male/female volunteers aged ≥18 and ≤ 45 years.
- •Body weight ≥ 50.0 kg for men and ≥ 45.0 kg for women, and body mass index (BMI) ≥18.5 and < 26.0 kg/m
- •Able to comply with the lifestyle restrictions.
排除标准
- •Subject has a history of allergy to any component of the investigational drug or similar drugs, or allergic constitution.
- •Subject has a current or past medical history that may affect the clinical trial or dysfunction, including but not limited to the past or current respiratory system, circulatory system, digestive system, urinary system, reproductive system, nervous system, endocrine system, immune system, motor system, blood system, psychiatry/ psychology, dermatology and other clinically serious diseases or chronic diseases; or any other diseases that may interfere with the test results.
- •Any surgical condition or condition may significantly affect the absorption, distribution, metabolism and excretion of the drug, or may pose a hazard to the subjects.
- •Subject has a history of surgery within 3 months prior to administration, or failure to recover from surgery, or having an expected surgical plan during the trial.
- •Subject has abnormal vital signs, laboratory abnormalities, and ECGs.
- •Subject has used any of over-the-counter products within 7 days or prescription medications within 28 days prior to dosing.
- •Subject positive for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), HIV antibody (HIV-Ab), or syphilis seroreactivity (Trust).
- •Subject has a history of alcohol abuse within 1 year or positive alcohol breath test results.
- •Subject has a history of substance abuse within 1 year or a positive urine drug screen.
- •Subject who has daily smoking of ≥ 5 cigarettes within 3 months.
- •Subject who has special requirements for food, cannot comply with the unified diet or have dysphagia.
- •Subject who has consumption of special diet (such as grapefruit, chocolate, coffee, xanthine-rich foods/drinks) within 48 hours prior to dosing and/or subject who has excessive daily consumption of tea, coffee, grapefruit juice, caffeinated beverages for nearly 3 months.
- •Subject who has participated in other clinical trials within 3 months before administration.
- •Subject has used blood products or being blood donor or blood loss within 3 months.
- •Pregnant, lactating women, or positive pregnancy test.
- •Subject who refusal to contraception, or plan to donate sperm or ovums.
- •Subject who has a history of needle or blood faintness.
- •Subject directly involved in this clinical trial.
- •Poor compliance or other conditions which would make participation in the study unsuitable.
研究组 & 干预措施
LY03017
Experimental
Ascending single oral doses of LY03017 in healthy adult subjects
干预措施: LY03017 (Drug)
Placebo
Placebo Comparator
LY03017-Placebo
干预措施: LY03017-Placebo (Drug)
结局指标
主要结局
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
时间窗: up to 216 hours
次要结局
- Maximum observed concentration (Cmax) of LPM526000133 in plasma(up to 216 hours)
- Time to maximum observed concentration (Tmax) of LPM526000133 in plasma(up to 216 hours)
- The area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞) of LPM526000133 in plasma(up to 216 hours)
- Area under the concentration-time curve from time zero to the time of last quantifiable concentration (AUC[0-last]) of LPM526000133 in plasma(up to 216 hours)
- Apparent terminal elimination half-life (t1/2) of LPM526000133 in plasma(up to 216 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A SAD, MAD and Food Effect Study to Evaluate the Safety, Tolerability, PK, and PD of AJA001 in Healthy SubjectsHealthy VolunteersNCT06019065AJNA Australia Pty Ltd64
已完成
1 期
Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910 in Healthy ParticipantsHealthyNCT05307978Alexion Pharmaceuticals, Inc.48
已完成
1 期
Phase 1, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of an Enterovirus D68-specific Monoclonal Antibody in Healthy AdultsEnterovirus InfectionNCT06444048National Institute of Allergy and Infectious Diseases (NIAID)36
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001 in Healthy ParticipantsDementia, FrontotemporalNCT06226064Vesper Biotechnologies ApS78
已完成
1 期
A phase 1, randomized, double-blind, placebo-controlled study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of VNA-318 in healthy male subjects2024-512106-26-02Vandria SA92